Guardant Health (GH)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$2.22 (+6.20%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Guardant Health (GH)
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Key Insights

Critical company metrics and information
  • Share Price

    $38.11
  • Market Cap

    $4.71 Billion
  • Total Outstanding Shares

    123.56 Million Shares
  • Total Employees

    1,779
  • Dividend

    No dividend
  • IPO Date

    October 4, 2018
  • SIC Description

    Services-medical Laboratories
  • Homepage

    https://www.guardanthealth.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-294.83 Million
Net Cash Flow From Operating Activities, Continuing$-51.06 Million
Net Cash Flow From Investing Activities, Continuing$-294.83 Million
Net Cash Flow$-346.87 Million
Exchange Gains/Losses$1.90 Million
Net Cash Flow From Financing Activities, Continuing$-2.88 Million
Net Cash Flow From Financing Activities$-2.88 Million
Net Cash Flow, Continuing$-348.77 Million
Net Cash Flow From Operating Activities$-51.06 Million

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Income/Loss From Continuing Operations Before Tax$-107.72 Million
Preferred Stock Dividends And Other Adjustments$0.00
Benefits Costs and Expenses$299.20 Million
Net Income/Loss Available To Common Stockholders, Basic$-107.75 Million
Revenues$191.48 Million
Basic Average Shares$123.05 Million
Diluted Average Shares$123.05 Million
Operating Income/Loss$-117.33 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Income Tax Expense/Benefit$30000.00
Diluted Earnings Per Share$0.88
Net Income/Loss$-107.75 Million
Operating Expenses$308.80 Million
Basic Earnings Per Share$0.88
Other Operating Expenses$221.50 Million
Costs And Expenses$308.80 Million
Income/Loss From Continuing Operations After Tax$-107.75 Million
Net Income/Loss Attributable To Parent$-107.75 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Research and Development$87.31 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Current Liabilities$197.34 Million
Liabilities And Equity$1.54 Billion
Intangible Assets$7.25 Million
Noncurrent Liabilities$1.40 Billion
Current Assets$1.23 Billion
Liabilities$1.60 Billion
Equity Attributable To Parent$-60.10 Million
Equity$-60.10 Million
Other Non-current Assets$179.59 Million
Inventory$72.30 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$1.54 Billion
Noncurrent Assets$312.01 Million
Accounts Payable$15.47 Million
Other Current Assets$1.15 Billion
Other Current Liabilities$181.87 Million
Fixed Assets$125.17 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.